Jnaps Biotech Thoughts Substack
Previewing OLMA's Big Proxy - JNap’s Biotech Thoughts
CRDF Trade and New Coverage - JNap’s Biotech Thoughts
CYTK Risk-Reward Ahead of ACACIA - JNap’s Biotech Thoughts
Previewing OLMA's Big Proxy - JNap’s Biotech Thoughts
CRDF Trade and New Coverage - JNap’s Biotech Thoughts
Big Video Update - Jan 2026 - JNap’s Biotech Thoughts
Previewing OLMA's Big Proxy - JNap’s Biotech Thoughts
Analytical Thoughts Substack | Substack
CYTK Risk-Reward Ahead of ACACIA - JNap’s Biotech Thoughts
CYTK Risk-Reward Ahead of ACACIA - JNap’s Biotech Thoughts
Advertisement Space (300x250)
Previewing OLMA's Big Proxy - JNap’s Biotech Thoughts
CRDF Trade and New Coverage - JNap’s Biotech Thoughts
Structured Thoughts | Substack
Biotech Pharma Investor | Substack
March 25 Updates - JNap’s Biotech Thoughts
Permanent Thoughts | Prof Mariann (Maz) Hardey | Substack
Biotech Pharma Investor | Substack
Quantitative Biotech Investing | Damian, Biotech Analyst | Substack
CRDF Trade and New Coverage - JNap’s Biotech Thoughts
Biotech Pharma Investor | Substack
Advertisement Space (336x280)
Biotech Pharma Investor | Substack
Biotech Blueprint | Katerina Roznik | Substack
Shortterm Thoughts | Substack
The Biotech Compass: Raw output - The Pharma Fox’s Substack
Substack Solution? My Thoughts on Fixing Substack Thumbnails
Biotech Blueprint | Katerina Roznik | Substack
Moderna: the most Overlooked Biotech Gem - Natan’s Substack
3 Biotech weekly base oddities (2026) - JT3's Substack
Trade Alert: Biotech - The Portfolio Armor Substack
Biotech Pharma Investor | Substack
Advertisement Space (336x280)
3 Biotech weekly base oddities (2026) - JT3's Substack
The Biotech Compass: Raw output - The Pharma Fox’s Substack
Chains of Thoughts | Amol Shah | Substack
Metodista Thoughts | Mighty | Substack
One Year on Substack - Thoughts and Observations
Beginning Thoughts - GonzalesJ's Substack